03
Oct
2016 Jul 259 141516-7. The aim of this study was to evaluate the stent thrombosis ST rate up to 3 years in patients with ST-segment elevation myocardial infarction STEMI treated by primary percutaneous coronary intervention PCI with new-generation drug-eluting stents n-DES compared with bare-metal stents BMS and old-generation drug-eluting stents o-DES enrolled in the SCAAR Swedish Coronary.
2016 Jul 259 141516-7.
New generation coronary stents. Bioabsorbable scaffolds have not demonstrated better outcomes than current standard treatment with second-generation drug-eluting stents but have showed a concerning signal of late and very late stent thrombosis. Everolimus-eluting stents have the most favorable outcomes in terms of safety as well as efficacy in patients undergoing percutaneous coronary intervention. Newer innovations such as biodegradable polymers and bioabsorbable scaffolds lack clinical data to replace second-generation.
Patients aged 80 years are often treated with new-generation drug-eluting stents DES but data from randomized studies are scarce owing to underrepresentation in most trials. We assessed 1-year clinical outcome of octogenarians treated with new-generation DES versus younger patients. As our experience with the next generation of bioabsorbable scaffolds grows it will be essential to continue long-term follow-up to assess whether newer-generation coronary stents will supplant current everolimus-eluting DES that have dominated modern-day PCI and potentially surgical revascularization in patients with multivessel coronary disease if very late stent thrombosis and late.
Drug-eluting stents are the mainstay in the treatment of coronary artery disease using percutaneous coronary intervention. Innovations developed to overcome the limitations of prior generations of stents include biodegradable polymer stents drug-eluting stents without a polymer and bioabsorbable scaffolds. Our review briefly discusses the clinical profiles of first- and second-generation coronary stents.
Contemporary second-generation drug-eluting stents DES have markedly improved outcomes in patients undergoing percutaneous coronary intervention by reducing the risk of restenosis stent thrombosis and myocardial infarction MI and may improve survival in comparison with bare metal stents and first-generation DES. 15 In comparison with first-generation DES contemporary. This new generation of DES has attempted to improve clinical safety by avoiding the presence of polymers.
The present preclinical in vivo study was designed to investigate the safety profile of Cre8 stent. This is a new coronary stent based on Amphilimus a sirolimus formulated with a polymer-free amphiphilic carrier released from reservoirs machined onto the abluminal stent surface. Few reports have primarily focused on long-term clinical outcomes in three-vessel disease when patients were treated with either first- or new-generation drug-eluting stents DES.
The purpose of this study was to investigate different clinical outcomes after percutaneous coronary intervention PCI for three-vessel disease with first- or new-generation DES. The study called the Bypass Surgery Versus Everolimus-Eluting Stent Implantation for Multivessel Coronary Artery Disease BEST trial is one of only two randomized controlled trials to compare bypass to angioplasty since the introduction of everolimus-eluting stents a new generation of drug-eluting stent. Percutaneous coronary intervention PCI is 40 years old this year.
From its humble beginnings of experimental work PCI has transitioned over years with coronary artery stenting now a standard medical procedure performed throughout the world. The conversion from plain old balloon angioplasty POBA to the present era of drug eluting stents DES has been driven by many. Background First-generation drug-eluting stents DES have become the most widely used devices worldwide for management of coronary artery disease.
As remote follow-up data were becoming available concerns emerged in regard to their long-term safety. Second-generation DES were designed to overcome safety issues but the results of randomised clinical trials remain conflicting. 2011 International Conference on Instrumentation Communication Information Technology and Biomedical Engineering 8-9 November 2011 Bandung Indonesia New Generation of Medical Implants.
Metallic Biodegradable Coronary Stent Hendra Hermawan12 Diego Mantovani2 1 Faculty of Biomedical Engineering and Health Science Universiti Teknologi Malaysia Malaysia Tel. JACC Cardiovasc Interv. 2016 Jul 259 141515-6.
2016 Jul 259 141516-7. The purpose of this study was to investigate the safety and efficacy of new-generation drug-eluting stents DES versus early-generation DES in women undergoing complex percutaneous coronary intervention CPCI. In the RESOLUTE All Comers trial the Resolute zotarolimus-eluting stent was non-inferior to the Xience V everolimus-eluting stent for the primary stent-related endpoint of target lesion failure cardiac death target vessel myocardial infarction and ischaemia-driven target lesion revascularisation at 1 year.
However data for long-term safety and efficacy from randomised studies of new generation drug-eluting coronary stents. Newer stents attempt to further lower the already low long-term risks of stent thrombosis and restenosis seen with current-generation DES see Everolimus- versus zotarolimus-eluting stents below. Stents that have been evaluated include those that have a bioresorbable also referred to as biodegradable polymer or those that are polymer free.
The aim of this study was to evaluate the stent thrombosis ST rate up to 3 years in patients with ST-segment elevation myocardial infarction STEMI treated by primary percutaneous coronary intervention PCI with new-generation drug-eluting stents n-DES compared with bare-metal stents BMS and old-generation drug-eluting stents o-DES enrolled in the SCAAR Swedish Coronary. Three vessel coronary artery disease represents one of the most severe forms of the disease and this clinical trial is important as it will assess a new generation of coronary stents for these. Supralimus and Supralimus-Core sirolimus-eluting stent Sahajanand Medical Technologies Pvt Ltd India are new generation DES that combine a thin stainless-steel platform Supralimus or cobalt-chromium platform Supralimus-Core a potent immunosuppressant agent Sirolimus and biodegradable drug-carrier components Figure 5.
The Intracoronary Stenting and Angiographic Results. Test Efficacy of Sirolimus- and Probucol-Eluting Versus Zotarolimus- Eluting Stents ISAR-TEST 5 trial is one of the largest clinical trials involving new-generation drug-eluting stents. In this study with inclusive enrollment criteria and powered for clinical end points 3002 patients were randomized to receive either polymer-free sirolimus- and probucol-eluting.
Subsequently various new types of coronary stent have been developed including DES with biocompatible polymers DES with biodegradable.